{
    "clinical_study": {
        "@rank": "146260", 
        "arm_group": {
            "arm_group_label": "Bevacizumab", 
            "arm_group_type": "Experimental", 
            "description": "Bevacizumab will be injected into the study eye at end of retinal detachment (rd) surgery and monthly for the following 3 months (total of 4 intravitreal bevacizumab injections)"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine the effects of a drug called bevacizumab (Avastin)\n      on the rates of recurrent retinal detachment and scar tissue formation."
        }, 
        "brief_title": "Eye Injections of Bevacizumab to See if Medication Helps to Lower Risk of Scar Tissue Development in the Retina and Repeated Retinal Detachment.", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Retinal Detachment", 
            "Vitreoretinopathy Proliferative"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Retinal Detachment", 
                "Vitreoretinopathy, Proliferative", 
                "Dissociative Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ability to provide written informed consent and comply with study assessments for the\n             full duration of the study\n\n          -  Undergoing pars plana vitrectomy with or without scleral buckling for recurrent RD\n             due to PVR with planned silicone oil instillation.\n\n        Exclusion Criteria:\n\n          -  Prior anti-VEGF (vascular endothelial growth factor) injections within 3 months of\n             retinal detachment surgery.\n\n          -  Traction retinal detachment due to proliferative diabetic retinopathy.\n\n          -  Inability to flatten retina completely intraoperatively\n\n          -  Known allergy or contraindication to intravitreal bevacizumab"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01860586", 
            "org_study_id": "HsuPVR13", 
            "secondary_id": "MARPVR2013"
        }, 
        "intervention": {
            "arm_group_label": "Bevacizumab", 
            "description": ".005 mL of Bevacizumab will be injected into the study eye, at the end of the surgical repair of the retinal detachment and at Month 1, 2 and 3.", 
            "intervention_name": "Bevacizumab", 
            "intervention_type": "Drug", 
            "other_name": [
                "Avastin", 
                "intravitreal injection"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "pvr", 
            "rd", 
            "Proliferative Vitreoretinopathy", 
            "retinal detachment", 
            "detachment"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19107"
                }, 
                "name": "Mid Atlantic Retina- Wills Eye Institute"
            }, 
            "investigator": [
                {
                    "last_name": "Jason Hsu, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Sunir Garg, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Marc Spirn, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Richard Kaiser, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Omesh Gupta, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Carl Park, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Joseph Maguire, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Carl Regillo, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Allen Ho, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Michael Dollin, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Christopher Brady, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "John Pitcher, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective Pilot Study Evaluating the Effect of Intravitreal Injection of Bevacizumab on Recurrent Retinal Detachment Due to Proliferative Vitreoretinopathy", 
        "other_outcome": {
            "description": "Increase or decrease in amount of letters read after intravitreal bevacizumab injections versus control patient that did not receive injections of intravitreal bevacizumab.", 
            "measure": "Intravitreal bevacizumab injections impact on visual acuity score (change in letters read).", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "overall_contact": {
            "email": "research@midatlanticretina.com", 
            "last_name": "Jessica Jordan", 
            "phone": "215-928-3092"
        }, 
        "overall_official": {
            "affiliation": "WillsEye Hospital", 
            "last_name": "Jason Hsu, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This will be assessed by the frequency (occurences) of retinal detachments in patients that have intravitreal bevacizumab injections versus prior patients that did not have intravitreal bevacizumab injections.", 
            "measure": "The effect of intravitreal bevacizumab injections on retinal detachment rate (increase or decrease)", 
            "safety_issue": "No", 
            "time_frame": "up to 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01860586"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Wills Eye", 
            "investigator_full_name": "Brian Burke, MPH", 
            "investigator_title": "Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "To determine if intravitreal bevacizumab injections will increase or decrease the occurences (cases) of recurrent PVR .", 
            "measure": "The effect of intravitreal bevacizumab injections on the development of recurrent Proliferative vitreoretinopathy (PVR).", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "Wills Eye", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wills Eye", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}